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OBJECTIVES: Cross-sectional research designs are often employed to answer ques-
tions in a timely, cost-effective manner. A common situation is nonresponse, where
missing or incomplete data may introduce bias when only the complete data are ana-
lyzed. In conducting a survey of type-2 Diabetes Mellitus (T2DM) patients with and
without symptoms of ADHD, HbA1c values, a primary measure of diabetes control, 
were obtained from 314 of 567 (55%) cases. Classiﬁ cation trees, a data-mining tool 
useful for predicting categorical responses, were used to examine the covariate related
pattern of the missing data. METHODS: The study design utilized an internet-based 
panel of 567 T2DM cases that consented to participate in a survey assessing the level 
to which ADHD symptoms, when present, impacted the ability to manage HbA1c and
other diabetes symptoms. In addition to de-identiﬁ ed demographic data, respondents
were asked to provide information on diabetes self-care, HbA1c values, ADHD 
symptoms, and health care resource utilization. Classiﬁ cation trees were used to 
develop a predictive model for the occurrence of missing HbA1c values. RESULTS: A
classiﬁ cation tree analysis revealed that the diabetes self-care score (SCI-R total score: 
n  567, mean  62.3, SD  15.9) was an important predictor of missing HbA1c.
Those respondents who had diabetes self-care scores below 51 were less likely to have 
provided an HbA1c. A high SCI-R total score indicates a high level of self-care, and 
the SCI-R total score has been found to correlate negatively with HbA1c, suggesting 
that better self-care is associated with better glycemic control. CONCLUSIONS: Clas-
siﬁ cation trees can be useful in understanding the structure of missing data. This
understanding is a ﬁ rst step in an analysis of a survey and can inﬂ uence decisions on 
the need for imputation of missing data and the imputation method.
PMC36
THE POPULATION IMPACT OF CHEMOTHERAPY IN LATE-STAGE
PROSTATE CANCER: A SIMULATION STUDY USING TAX327 AND
SEER-MEDICARE DATA
Onukwugha E1, Mullins CD1, Seal B2, Hussain A3
1University of Maryland School of Pharmacy, Baltimore, MD, USA, 2Sanoﬁ -Aventis, 
Bridgewater, NJ, USA, 3University of Maryland School of Medicine, Baltimore, MD, USA
OBJECTIVES: Simulation studies can be used to estimate or forecast drug effectiveness 
in a representative sample by translating a survival beneﬁ t established in a clinical
trial. The methods of this translation have not been described. The present study 
describes how the translation is operationalized using a combination of clinical trial
and observational data. We simulate the population impact of docetaxel (D), the ﬁ rst
chemotherapy agent to demonstrate a survival beneﬁ t in patients with hormone refrac-
tory prostate cancer (HRPC). The survival beneﬁ t of D was established in the TAX327 
trial however it is unclear how the beneﬁ t may translate to a heterogeneous population 
of patients. METHODS: A combination of TAX327 trial data and SEER-Medicare 
(SM) data were used. In pts age 69 and randomized to D (every 3 weeks, D3P) 
or mitoxantrone (M), trial data showed a survival beneﬁ t for D. Accordingly, 3,515 
SM pts age 69, diagnosed with M1 PC between 1994 and 2002, and receiving 
only androgen deprivation therapy (ADT) were selected. Graphical plots and likeli-
hood ratio tests were used to identify the best-ﬁ tting parametric survival functions 
for D3P, M, and SM patients. Candidate (selected) curves included: gamma, log-
normal, weibull, exponential, and polynomial (log-logistic) functions. The survival 
beneﬁ t function from the trial was calculated using parametric curves ﬁ tted to 
D3P and M data and subsequently imposed on the SM survival curve. The simulated
beneﬁ t was assessed in 3 scenarios depending on the assumed time of chemotherapy 
initiation: at diagnosis of M1 PC, at 12 mos post-diagnosis, and at 24 mos post-
diagnosis. The simulated beneﬁ t in the SM sample was examined following adjust-
ments for sample heterogeneity due to demographic, clinical, and ecologic factors.
RESULTS: We ﬁ nd that the simulated survival beneﬁ t is sensitive to adjustments for
sample heterogeneity and also is sensitive to assumptions regarding the time of che-
motherapy initiation.
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OBJECTIVES: The objective of this paper is to empirically compare inverse probabil-
ity of treatment weights (IPTW) adjustment with propensity score matching method 
using the Thomson Reuter’s MarketScan commercial claims database. METHODS:
There are three treatment groups in this study: treatment with nasal corticosteroids,
with nasal antihistamines and combination treatment. We applied both the IPTW 
method and the traditional matching by propensity scores. In the propensity score 
matching, we used nearest neighbor method to match the patients in the nasal corti-
costeroids group with those in the antihistamines group. A second matching was 
implemented between the nasal corticosteroids and combination treatment group. 
Alternatively, a generalized multinomial logit model was estimated to obtain the pro-
pensity scores. The conditional probabilities of receiving the particular type of treat-
ment given the pre-treatment factors were used as the generalized propensity scores.
A propensity score weight, also referred to as IPTW, was calculated for each case in
each treatment group as the inverse of the generalized propensity score. Descriptive
Statistics were obtained and difference between the groups tested after applying IPTW
and propensity score matching. Logistics regressions of probability of any respiratory 
infection were estimated using both methods. We compared the point estimates and 
standard errors of treatment effect using two methods. RESULTS: Both IPTW and
propensity score matching methods reduced the differences in the pre-treatment factors
across treatment groups. In the multivariate regressions, patients treated with cortico-
steroids were found to have signiﬁ cantly lower probability to have any respiratory 
infection compared with those treated with intranasal antihistamine when using the 
propensity score matched sample. However, using the IPTW method, we found that
the treatment effects had larger standard errors and were not signiﬁ cant. CONCLU-
SIONS: IPTW is less time-consuming compared with traditional matching procedure.
However, the IPTW weighting method generates bigger standard errors compared with
the traditional matching method.
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OBJECTIVES: Suitable long-term data are rarely available when reimbursement deci-
sions are made for T2DM drugs. If properly constructed and applied, economic simula-
tion models can be useful tools for decision-making. To provide conﬁ dence that model
results reﬂ ect reality, the ability of these models to replicate results from actual clinical
studies should be assessed with formal validity tests. The objective of this study was to
assess the validity of a new economic simulation model of T2DM. METHODS: The 
economic simulation model of T2DM is a stochastic, micro-simulation model that
consists of Markov health states representing the development and consequences of key 
micro- and macro-vascular diabetes complications. Model predictions for 82 outcomes 
covering 16 different patient populations from six published outcomes studies were
generated by replicating the health and demographic proﬁ les of each patient popula-
tion, applying the study inclusion/exclusion criteria and treatments, and then simulat-
ing outcomes for an equivalent length of time. Where published data were incomplete 
for a study, the most suitable data from other studies were used. Predicted outcomes
were plotted against observed outcomes to assess model ﬁ t, as all points would lie on 
the unit line when the predicted and observed values match exactly. The predictive ﬁ t
was assessed both overall and separately by whether the source data were or were not
used in model construction. RESULTS: The best-ﬁ tting line through the cluster plot of 
predicted versus actual outcomes emanated from the origin with slope 1.07. The result-
ing R2 was 0.95. The model predicted outcomes for internal and external studies
equally well, with R2 values of 0.95 and 0.97, respectively. CONCLUSIONS: Results 
suggest the model corresponds well with actual clinical data, even considering studies
not used in model construction. Though model-based results must always be inter-
preted cautiously, the model can be considered a useful decision-making tool.
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OBJECTIVES: Since its introduction in 2000, PCV7 vaccination in infants and young
children has dramatically reduced the overall incidence of invasive pneumococcal
disease (IPD) in children and adults. We developed an age-structured, transmission-
dynamic model to quantify these direct and indirect beneﬁ ts of infant PCV7 vaccina-
tion based on US surveillance data from the years 2000–2005. In the present analysis,
the model was updated to include data from the years 2006 and 2007. METHODS:
The mathematical model simulates the acquisition of asymptomatic carriage of pneu-
mococci and the development of fatal and non-fatal IPD among vaccinated and 
unvaccinated individuals aged 2, 2–4, 5–64, and 65 years old. The model was 
parameterized by approximating IPD surveillance data, supplemented with published 
literature. The original model was able to adequately replicate the observed incidence
of IPD cases and deaths from the years 2000–2005. By modifying key infection 
transmission parameters, the model was recalibrated to ﬁ t the most current surveil-
lance data available (2000–2007). RESULTS: From 2001–2005, a decline in IPD was 
observed in nearly every age group. Predictions from the original model indicated the
IPD decline would continue in years 2006 and 2007. However, actual surveillance
data show IPD incidence remained stable from 2005–2007, potentially a result of very 
high – but not complete – vaccine coverage and effectiveness or the continued or 
increased presence of IPD caused by pneumococcal serotypes not included in PCV7. 
The recalibrated model maintained the indirect beneﬁ t of infant vaccination to the 
older, unvaccinated populations demonstrating ^35% fewer IPD cases in the 65 
year age group ﬁ ve years after PCV7 introduction. CONCLUSIONS: The improved 
epidemiologic model simulates the observed US surveillance data to date. By modifying 
key input parameters, this model can be used to simulate the impact of various vacci-
nation strategies in the US and other developed countries.
